Our portfolio of services at Inaphaea is consistently growing, and we are pleased to announce our collaboration in-vitro liver cell assay service with DefiniGEN for profiling drug candidates for liver disease and liver toxicity using their in vitro, IPSC-derived, hepatocyte assays.

DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimising risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionising liver models for efficacy and toxicology screening, utilising a platform that enables the large-scale generation of hepatocyte-like cells (Opti-Heps) with functional relevance comparable to human primary cells.

Our Opti-Heps effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our Opti-Heps successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.

For further details please see https://www.definigen.com/